182 related articles for article (PubMed ID: 32075363)
1. Patterns of Hydroxyurea Prescription and Use in Routine Clinical Management of Polycythemia Vera: A Multicenter Chart Review Study.
Büyükaşık Y; Ali R; Turgut M; Saydam G; Yavuz AS; Ünal A; Ar MC; Ayyıldız O; Altuntaş F; Okay M; Çiftçiler R; Meletli Ö; Soyer N; Mastanzade M; Güven Z; Soysal T; Karakuş A; Yiğenoğlu TN; Uçar B; Gökçen E; Tuğlular T
Turk J Haematol; 2020 Aug; 37(3):177-185. PubMed ID: 32075363
[TBL] [Abstract][Full Text] [Related]
2. Real-World Dosing Patterns of Ruxolitinib in Patients With Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea.
Altomare I; Parasuraman S; Paranagama D; Kish J; Lord K; Yu J; Colucci P
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e915-e921. PubMed ID: 34353779
[TBL] [Abstract][Full Text] [Related]
3. Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera.
Parasuraman SV; Shi N; Paranagama DC; Bonafede M
J Manag Care Spec Pharm; 2018 Jan; 24(1):47-55. PubMed ID: 29290171
[TBL] [Abstract][Full Text] [Related]
4. A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study.
Barbui T; Vannucchi AM; Finazzi G; Finazzi MC; Masciulli A; Carobbio A; Ghirardi A; Tognoni G
Am J Hematol; 2017 Nov; 92(11):1131-1136. PubMed ID: 28699191
[TBL] [Abstract][Full Text] [Related]
5. [Treatment with hydroxyurea of polycythemia vera in a 11 year-old child].
Vodoff MV; Nelken B; Vic P; Farriaux JP
Arch Pediatr; 1996 Sep; 3(9):870-3. PubMed ID: 8949347
[TBL] [Abstract][Full Text] [Related]
6. Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera.
Crodel CC; Jentsch-Ullrich K; Reiser M; Jacobasch L; Sauer A; Tesch H; Ulshöfer T; Wunschel R; Palandri F; Heidel FH
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2693-2705. PubMed ID: 34807311
[TBL] [Abstract][Full Text] [Related]
7. From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera.
Fruchtman SM; Mack K; Kaplan ME; Peterson P; Berk PD; Wasserman LR
Semin Hematol; 1997 Jan; 34(1):17-23. PubMed ID: 9025158
[No Abstract] [Full Text] [Related]
8. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
Gisslinger H; Klade C; Georgiev P; Krochmalczyk D; Gercheva-Kyuchukova L; Egyed M; Rossiev V; Dulicek P; Illes A; Pylypenko H; Sivcheva L; Mayer J; Yablokova V; Krejcy K; Grohmann-Izay B; Hasselbalch HC; Kralovics R; Kiladjian JJ;
Lancet Haematol; 2020 Mar; 7(3):e196-e208. PubMed ID: 32014125
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and Safety of Ruxolitinib in Polycythemia Vera].
Chang L; Duan MH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1515-1518. PubMed ID: 36208258
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of polycythemia. II.--Comparison of hydroxyurea with pipobroman in 294 patients less than 65 years of age].
Najean Y; Rain JD; Lejeune F; Echard M; Fermand JP; Gruyer P; Brahimi S
Ann Med Interne (Paris); 1998 Mar; 149(2):94-100. PubMed ID: 11490531
[TBL] [Abstract][Full Text] [Related]
11. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
Girodon F; Schaeffer C; Cleyrat C; Mounier M; Lafont I; Santos FD; Duval A; Maynadié M; Hermouet S
Haematologica; 2008 Nov; 93(11):1723-7. PubMed ID: 18728027
[TBL] [Abstract][Full Text] [Related]
12. Management of polycythemia vera with hydroxyurea.
Tatarsky I; Sharon R
Semin Hematol; 1997 Jan; 34(1):24-8. PubMed ID: 9025159
[No Abstract] [Full Text] [Related]
13. Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database.
Tremblay D; Ronner L; Podoltsev N; Gotlib J; Heaney M; Kuykendall A; O'Connell C; Shammo JM; Fleischman A; Mesa R; Yacoub A; Hoffman R; Moshier E; Zubizarreta N; Mascarenhas J
Leuk Res; 2021 Oct; 109():106629. PubMed ID: 34082375
[TBL] [Abstract][Full Text] [Related]
14. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.
Alvarez-Larrán A; Pérez-Encinas M; Ferrer-Marín F; Hernández-Boluda JC; Ramírez MJ; Martínez-López J; Magro E; Cruz Y; Mata MI; Aragües P; Fox ML; Cuevas B; Montesdeoca S; Hernández-Rivas JA; García-Gutiérrez V; Gómez-Casares MT; Steegmann JL; Durán MA; Gómez M; Kerguelen A; Bárez A; García MC; Boqué C; Raya JM; Martínez C; Albors M; García F; Burgaleta C; Besses C;
Haematologica; 2017 Jan; 102(1):103-109. PubMed ID: 27686377
[TBL] [Abstract][Full Text] [Related]
15. Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study.
Theocharides A; Gisslinger H; De Stefano V; Accurso V; Iurlo A; Devos T; Egyed M; Lippert E; Delgado RG; Cantoni N; Dahm AEA; Sotiropoulos D; Houtsma E; Smyth A; Iqbal A; Di Matteo P; Zuurman M; Te Boekhorst PAW
Eur J Haematol; 2024 Mar; 112(3):379-391. PubMed ID: 37899734
[TBL] [Abstract][Full Text] [Related]
16. Busulfan versus hydroxyurea in the treatment of polycythemia vera (PV) and essential thrombocythemia (ET).
Brodsky I
Am J Clin Oncol; 1998 Feb; 21(1):105-6. PubMed ID: 9499248
[No Abstract] [Full Text] [Related]
17. Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available.
Foltz L; Pica GM; Zerazhi H; Van Droogenbroeck J; Visanica S; Báez de la Fuente E; Leber B; de Almeida AM; Ranta D; Kiladjian JJ; Chrit L; Kandra A; Morando J; Devos T
Leuk Lymphoma; 2019 Dec; 60(14):3493-3502. PubMed ID: 31359808
[TBL] [Abstract][Full Text] [Related]
18. Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis.
Demuynck T; Verhoef G; Delforge M; Vandenberghe P; Devos T
Ann Hematol; 2019 Jun; 98(6):1421-1426. PubMed ID: 30919072
[TBL] [Abstract][Full Text] [Related]
19. Polycythemia Vera Management and Challenges in the Community Health Setting.
Gerds AT; Dao KH
Oncology; 2017; 92(4):179-189. PubMed ID: 28095380
[TBL] [Abstract][Full Text] [Related]
20. Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study.
Grunwald MR; Kuter DJ; Altomare I; Burke JM; Gerds AT; Walshauser MA; Savona MR; Stein B; Oh ST; Colucci P; Parasuraman S; Paranagama D; Mesa R
Clin Lymphoma Myeloma Leuk; 2020 Apr; 20(4):219-225. PubMed ID: 32063527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
